CHICAGO--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced results from a sub-analysis of the PLATO genetic sub-study that evaluated the impact of poor metabolizers of clopidogrel. Data suggests results were consistent with the overall outcome of the PLATO study, with BRILINTA (ticagrelor) compared to clopidogrel, even after poor clopidogrel metabolizers were excluded. Results of this sub-analysis were presented today at the American College of Cardiology Scientific Sessions (ACC), in Chicago, Ill.
